Argent Biopharma ( (AU:RGT) ) has shared an update.
Argent BioPharma Ltd. has entered a strategic collaboration with David Trading Ltd. to operate its EU-GMP facility in Malta for 49 years. This agreement allows David Trading Ltd. to manage and financially support the facility, ensuring the continued production of CimetrA™ and potentially expanding the product portfolio. The collaboration is expected to reduce operational costs by up to USD $1 million annually for Argent BioPharma, enhancing operational efficiency and profitability. Additionally, David Trading Ltd. has an option to acquire the facility’s shares, subject to regulatory approval, which could further solidify the partnership and expand production capabilities, positioning Malta as a competitive hub for pharmaceutical manufacturing.
More about Argent Biopharma
Argent BioPharma Ltd. operates in the pharmaceutical industry, specializing in the production of liquid dose forms. The company focuses on manufacturing CimetrA™, a product produced in its EU-GMP-certified facility in Malta, which was established with support from the Maltese government.
YTD Price Performance: -52.50%
Average Trading Volume: 100,478
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.13M
See more insights into RGT stock on TipRanks’ Stock Analysis page.